Firebrick Pharma (ASX:FRE) — Material Events
ASX:FRE · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Firebrick Pharma Unlocks Indonesia Market with Nasodine ApprovalMedium
Firebrick Pharma secures first regulatory approval for Nasodine in Indonesia, unlocking Southeast Asia market
27 Mar 2026
·Regulatory Approval and Partnership Agreement
·80
Firebrick Pharma Accelerates Growth with Nasodine Throat Spray Launch and 15% Sales BoostMedium
Firebrick Pharma launches Nasodine Throat Spray in Singapore, reports 15% sales growth and cost reductions
28 Jan 2026
·Quarterly Activity Report and Appendix 4C
·80
Firebrick Pharma Advances Southeast Asia Expansion with Indonesia Approval and $1.5M RaiseMedium
Firebrick Pharma achieves Indonesia approval, launches new product, raises $1.5M for expansion
21 Apr 2026
·Quarterly Activity Report
·80
Firebrick Pharma’s Nasodine Trial Validated, Sales Climb but Funding Falls ShortMedium
Firebrick Pharma publishes positive Phase 3 Nasodine trial results, reports sales growth, but faces funding shortfall
23 July 2025
·Quarterly Activity Report
·75
Firebrick Pharma’s Nasodine Sales Surge Amid Rising Losses and Market ExpansionMedium
Firebrick Pharma reports strong Nasodine sales growth but wider net loss in FY25
29 Aug 2025
·Annual Financial Report
·75
Firebrick Pharma Secures $1.4M to Boost Nasodine Growth in US and AsiaMedium
Firebrick Pharma raises $1.4M via share placement to fund Nasodine expansion and new product development
26 Aug 2025
·Capital Raising
·75
Firebrick Pharma Launches Nasodine Throat Spray in Singapore, Eyes Global ExpansionMedium
Firebrick Pharma launches Nasodine Throat Spray in Singapore, plans further 2026 international rollouts
21 Jan 2026
·Product Launch Announcement
·75
Firebrick Pharma Launches Nasodine Throat Spray Amid $1.26M Half-Year LossMedium
Firebrick Pharma reports $1.26M half-year loss, launches Nasodine Throat Spray in Singapore and Fiji, eyes Philippines approval
24 Feb 2026
·Appendix 4D Half-Year Financial Report
·75
Firebrick Pharma Raises $1.5M to Fuel New Product Push and ExpansionMedium
Firebrick Pharma Raises $1.5M via Placement with Attaching Options
31 Mar 2026
·Capital Raising
·75
Firebrick Pharma Boosts Philippines Stake Ahead of Nasodine LaunchMedium
Firebrick Pharma Raises $102K from Philippines Partner to Boost Stake Ahead of Nasodine Launch
16 Oct 2025
·Capital Raising
·70
Firebrick Pharma Expands Nasodine Reach, Slashes Marketing Costs with Innorini DealMedium
Firebrick Pharma licenses Nasodine distribution to Innorini across four Asian markets, cutting marketing costs
26 Aug 2025
·License Agreement
·70
Firebrick Pharma Boosts Cash Reserves, Expands Nasodine Reach in Southeast AsiaMedium
Firebrick Pharma expands Nasodine markets, reports $1.94M cash reserves after $1.4M placement
23 Oct 2025
·Quarterly Activity Report
·70
No articles in this tier for the last 12 months.
Market Mentions
6
- appeared in market wrap coverage
These are market wrap articles where Firebrick Pharma (ASX:FRE) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026
28 Mar 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026